Travere Therapeutics, Inc. (TVTX) Form 8-K — Sep 21, 2026
Travere Therapeutics announced on September 21, 2026 that Eric Dube, Ph.D., will step down as President and CEO and leave the Board effective December 1, 2026, under a mutually agreed transition timeline. Bradley L. Campbell has been named as his successor, becoming President and CEO and joining the board on the same date. Campbell, 51, served as President and CEO of Amicus Therapeutics from August 2022 until its April 2026 acquisition by BioMarin Pharmaceutical, and brings over 25 years of biopharmaceutical experience, including leading the commercialization of Galafold and prior roles at Genzyme and Bristol-Myers Squibb.
Key figures
- Expense Payment
- 500000
- Incoming Ceo Base Salary
- 1000000
- Inducement Option Value
- 8250000
- Legal Fee Reimbursement
- 10000
- Consulting Period Months
- 18
- Officer Resignation Date
- 2026-12-01
- Employment Termination Date
- 2027-02-16
- Incoming Ceo Target Bonus Pct
- 85
- Inducement Psu Value Early2027
- 3750000
- Inducement Time Based Rsu Value
- 8250000
- Severance Multiple Change In Control
- 2
- Severance Multiple Non Change In Control
- 1.5
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.